Introduction {#sec1}
============

In recent years there has been a significant focus on eradicating disparities in health care due to race, sex, and region of residence throughout the world. As endorsed by the Institute of Medicine and Healthy People 2020 Agenda, the principle goal is to "improve access to comprehensive, quality health care services" for everyone \[[@cit0001]\]. Towards this perspective, successful health care systems have to maximise health gains for the entire population and simultaneously minimise the need for expensive medical care. Off-patent medicines, like generic and bioequivalent drugs, can support this objective, offering high-quality treatment at lower costs \[[@cit0002], [@cit0003]\]. Although substitution of branded medications with less expensive generic equivalents has been introduced worldwide, a high percentage of both professionals and the general public exhibit negative views on the safety and/or effectiveness of generic drugs compared with branded ones. Acceptance of generics appears to be higher in patients with higher levels of education, while patients from lower socioeconomic demographic groups tend to have greater mistrust of these drugs \[[@cit0004]\]. In this regard, the Greek population perceives generics as being less effective and safe compared to on-/off-patent branded originator drugs, despite the fact that Greek legislation has set economic incentives in an effort to increase the use of these drugs \[[@cit0005]\]. Among this population, those with low income and young people are more likely to exhibit negative views on safety and/or effectiveness of generic drugs \[[@cit0006]\].

Cardiovascular disease (CVD) is an example of non-communicable diseases in which adequate treatment and access to a health care system is a decisive parameter in the spectrum of primary and secondary prevention, and generic drugs are increasingly investigated to be included in treatment of these patients \[[@cit0002]\]. To this issue, generic clopidogrel formulations are now used for the prevention of thrombosis in CVD patients, due to their low costs \[[@cit0007]\]. The use of these generic drugs should be widely adapted; not only in large urban centres with well-qualified health care facilities but also in remote areas with limited access to hospitals and health care services, such as islands and areas with high altitude \[[@cit0008], [@cit0009]\]. Examining the use as well as the efficacy and safety of generic versus original clopidogrel formulations in CVD patients in these areas is of particular interest due to the different lifestyle of this population compared with urban regions in terms of less stress and higher adherence to healthy dietary patterns, i.e. Mediterranean diet \[[@cit0010]--[@cit0012]\].

The aim of the Aegean prospective study was to evaluate the 12-month incidence of recurrent adverse cardiovascular events and major haemorrhage in acute coronary syndrome (ACS) patients treated with original clopidogrel or a generic clopidogrel formulation in relation to their sociodemographic factors, region of residence, i.e. insular (Aegean sea islands) or urban areas of Greece (Attica region), and clinical characteristics.

Material and methods {#sec2}
====================

Sample {#sec2.1}
------

The Aegean study is a prospective, observational cohort. During 2015--2016, a total of 1194 consecutive Greek patients with diagnosis of an ACS, i.e. acute myocardial infarction (AMI) or unstable angina (UA), who were hospitalised in the Cardiology Department of Tzaneio General Hospital in Piraeus, Attica region and in the departments of General Hospitals in the Aegean Sea islands, were enrolled (participation rate of the initially approached ACS patients was 80% in urban area and 95% in Aegean Sea islands). The particular hospitals were selected to represent both urban areas and insular areas. Of the total enrolled patients, 740 (69% men and 31% women) were from urban areas and 454 from insular areas (73% men and 27% women). Power analysis showed that the number of enrolled participants was adequate to evaluate two-sided differences between groups of the study and the investigated parameters greater than 20 ±5%, achieving statistical power greater than 0.80 at a 5% probability level (*p*-value).

Defining ACS patients {#sec2.2}
---------------------

At hospital entry, as well as during hospitalisation, a clinical examination was performed in all patients and a complete biochemical analysis including biomarkers of cardiac injury was performed. The diagnosis of acute myocardial infarction (AMI), characterised either as ST-segment elevation (STEMI) or as high-risk unstable angina (UA) or AMI without ST elevation (UA/NSTEMI), was performed according to the Third Universal Definition of Myocardial Infarction \[[@cit0013]\]. ACS patients had to meet at least one of the five following diagnostic criteria: 1. symptoms of ischaemia; 2. new (or presumably new) significant ST/T wave changes or left bundle-branch block; 3. development of pathological Q waves on electrocardiogram (ECG); 4. imaging evidence of new loss of viable myocardium or regional wall motion abnormality; 5. identification of intracoronary thrombus by angiography or autopsy \[[@cit0013]\]. In addition, the levels of high-sensitivity troponin I (hs-TnI) were used as the cardiac biomarker of necrosis \[[@cit0013]\]. Medical information of the patients was retrieved through hospital records.

Measurements at baseline examination {#sec2.3}
------------------------------------

The baseline examination included a range of patients' characteristics, selected through a case report form, and including, among others: age, gender, smoking habits, individual medical history, and family history of CVD. Specifically, years of smoking were recorded; current smokers were defined as those who smoked at least one cigarette per day or had stopped smoking during the past 12 months, while the rest were defined as past smokers; the remaining patients were defined as never or rare smokers. Regarding anthropometric characteristics, the body mass index (BMI) was calculated.

Using patients' medical files, history of stroke, heart vessel disease, atrial fibrillation, peripheral artery disease, carotid artery disease, heart failure, New York Heart Association (NYHA) functional classification, liver disease, neoplasm, and thyroid disease were recorded. Baseline assessment of other clinical characteristics (i.e. history of hypertension, hypercholesterolaemia, and diabetes mellitus) was based on the information retrieved through physical examination, as well as patients' medical records and pharmaceutical management \[[@cit0012], [@cit0014]\]. The antiplatelet medical treatment prescribed to patients was evaluated in terms of original clopidogrel hydrogen sulphate salt (Plavix^®^/Iscover^®^) or generic clopidogrel besylate formulation (Clovelen^®^) (600 mg loading dose, 75 mg/day), administered in addition to aspirin (325 mg loading dose, 100 mg/day). The clopidogrel treatment pattern was also evaluated and defined as exclusive use of generic clopidogrel or transition from original to generic clopidogrel.

Follow-up {#sec2.4}
---------

A 12-month follow-up was performed, and information from all patients was available (i.e. 0% loss to follow-up rate). The clinical endpoint of the present study was the composite of recurrent AMI, ischaemic stroke, cardiac deaths, or hospitalisation due to a major haemorrhage, as classified according to the International Society for Thrombosis and Haemostasis (ISTH): 1. fatal bleeding and/or 2. symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome; and/or 3. bleeding causing a fall in haemoglobin level of 2 g/dl (1.24 mmol/l) or more, or leading to transfusion of two or more units of whole blood or red cells \[[@cit0015]\]. The all-cause mortality was also recorded. The follow-up was performed by outpatient visits or by phone visits. For the participants who died during the follow-up, the information was obtained from their relatives, as well as from death certificates. As regards individuals who might have first suffered from stroke and then had an AMI, it was a-priori decided that the first outcome would be considered as the end-point, but also to record the consequent event for further testing of competing risks (however, there were no such cases in the sample).

Ethical consideration {#sec2.5}
---------------------

The study protocol was submitted to the Medical Research Committees of the participating Institutions, and the project was approved. The institutional review boards of Atherothrombosis Research Centre, Tzaneio Hospital of Piraeus, Skylitseio General Hospital of Chios, and the National Hospital of Kalymnos, Greece ensured that the study was carried out in accordance with the Declaration of Helsinki (1989) of the World Medical Association and its amendments. All participants were informed about the aims and procedures of the study and signed an informed consent form.

Statistical analysis {#sec2.6}
--------------------

Continuous variables are presented as mean and standard deviation (SD), whereas categorical variables are shown as absolute and relative (%) frequencies. The association between normally distributed continuous variables (BMI, age) and patients' gender was evaluated through the Student's *t*-test for independent samples. Whether these variables were normally distributed was tested through the P-P plot and equality of variances through the Levene's test. Associations between the categorical variables and gender were tested through the χ^2^ test. To evaluate the association between antiplatelet treatment (in terms of generic vs. original clopidogrel and exclusive vs. non-exclusive use of generic clopidogrel) and 12-month clinical endpoint, logistic regression analysis was performed. Results are presented as odds ratios (OR) and their corresponding 95% confidence intervals (95% CI). Time to event was also taken into account, and Cox proportional hazards models were also applied, but it was decided to keep the results from logistic regression because the models had better correct classification rates for the cases and some time-points were missing. STATA software version 14 (MP & Associates, Sparta, Greece) was used for all statistical analyses.

Results {#sec3}
=======

In [Table I](#t0001){ref-type="table"}, baseline characteristics of the ACS patients, as well as their 12-month outcome, are presented. Among ACS patients, 386 (32%) presented with STEMI and 808 (68%) presented with UA/NSTEMI. The overall generic and original clopidogrel use was 87% and 13%, respectively; the generic drug use in insular areas being 81%, while in urban being significantly higher, i.e. 90% (*p* \< 0.001).

###### 

Baseline characteristics of acute coronary syndrome patients participated in Aegean epidemiological study and 12-month clinical endpoint (*n* = 1194)

  Baseline characteristics                               Aegean Sea Islands (*n* = 454)   Urban areas (*n =* 740)                                        
  ------------------------------------------------------ -------------------------------- ------------------------- ---------- ------------ ------------ ----------
  Age \[years\]                                          65 (12)                          69 (13)                   0.02       65 (11)      71 (10)      \< 0.001
  Body mass index \[kg/m^2^\]                            28.4 (4.4)                       28.7 (7.4)                0.64       28.2 (4.0)   28.7 (5.6)   0.24
  Current smoking, *n* (%)                               174 (52)                         20 (23)                   \< 0.001   297 (58)     74 (33)      \< 0.001
  Hypercholesterolemia, *n* (%)                          221 (66)                         70 (83)                   0.49       425 (83)     177 (78)     0.03
  Hypertension, *n* (%)                                  211 (63)                         66 (78)                   0.59       384 (75)     186 (82)     0.03
  Diabetes mellitus, *n* (%)                             103 (31)                         33 (39)                   0.67       169 (33)     86 (38)      0.15
  Acute myocardial infarction, *n* (%)                   187 (56)                         42 (50)                   0.01       261 (51)     93 (41)      0.01
  Family history of CVD, *n* (%)                         60 (18)                          8 (9)                     0.009      138 (27)     45 (20)      0.04
  Heart Failure, *n* (%)                                 60 (18)                          13 (15)                   0.13       128 (25)     49 (22)      0.33
  NYHA class, *n* (%):                                                                                                                                   
   Class I                                               271 (81)                         103 (87)                  0.35       384 (75)     179 (79)     0.50
   Class II                                              13 (4)                           3 (4)                     0.35       41 (8)       6 (10)       0.50
   Class III                                             29 (8)                           3 (4)                     0.35       61 (12)      27 (9)       0.50
   Class IV                                              23 (7)                           7 (5)                     0.35       25 (5)       3 (2)        0.50
  Peripheral artery disease, *n* (%)                     60 (18)                          27 (32)                   0.03       61 (12)      13 (29)      0.67
  Carotid artery disease, *n* (%)                        37 (11)                          15 (17)                   0.19       82 (16)      26 (59)      0.01
  Heart valve disease, *n* (%)                           43 (13)                          9 (10)                    0.23       30 (6)       14 (31)      0.001
  Atrial fibrillation, *n* (%)                           27 (8)                           11 (13)                   0.32       30 (6)       8 (18)       0.28
  Antiplatelet treatment status, *n* (%):                                                                                                                
   Exclusive use of original clopidogrel                 54 (16)                          15 (12)                   0.002      46 (9)       25 (11)      0.60
   Total use of generic clopidogrel                      281 (84)                         104 (88)                  0.007      467 (91)     202 (90)     0.85
   Exclusive use of generic clopidogrel                  197 (59)                         62 (73)                   0.61       296 (67)     131 (65)     0.03
   Transition from original to generic clopidogrel       84 (25)                          42 (27)                   0.61       171 (33)     71 (35)      0.03
  12-month follow-up:                                                                                                                                    
   Composite CVD endpoint, *n* (%)                       17 (5.0)                         4 (4.2)                   0.78       20 (4.3)     6 (3.2)      0.67
   Recurrent AMI, *n* (%)                                10 (2.7)                         3 (2.2)                   0.39       6 (1.5)      0 (0)        0.10
   Ischaemic stroke, *n* (%)                             1 (0.3)                          0 (0)                     0.55       4 (0.8)      1 (0.6)      0.88
   Cardiac deaths, *n* (%)                               3 (1)                            0 (0)                     0.30       5 (1)        3 (1.3)      0.47
   Hospitalisation due to a major haemorrhage, *n* (%)   3 (1)                            1 (1)                     0.75       5 (1)        2 (1)        0.90
   All-cause mortality, *n* (%)                          6 (1.9)                          1 (1)                     0.36       10 (2)       5 (2.2)      0.37

Data are presented as mean (standard deviation, SD). P-values were obtained using the Student's t-test for age and body mass index and the χ^2^ test for the rest (categorical) of the variables. CVD -- cardiovascular disease, NYHA -- New York Heart Association Functional Classification.

At 12 months of follow-up the clinical endpoint (the composite of recurrent AMI, ischaemic stroke, cardiac deaths, or hospitalisation due to a major haemorrhage) had occurred in 47 patients out of 1194 (3.9%) (4.6% in Aegean islands and 3.5% in urban areas, *p* = 0.34). No difference in the clinical endpoint was observed between genders (4.0% in men and 3.8% in women patients; *p* = 0.86). The distribution of the endpoint was AMI 40%, followed by cardiac deaths 23%, ischaemic stroke events 13%, and the remaining 24% were re-hospitalisations due to major bleeding. Although no differences were observed between regions in the composite clinical endpoint, as regards recurrent AMI events, the 12-month incidence rate was 2.5% in Aegean islands versus 0.8% in urban areas (*p* = 0.003). As for all-cause mortality, no significant difference was observed between the two regions (*p* \> 0.05) ([Table I](#t0001){ref-type="table"}).

Also, no significant differences were observed between those who presented a clinical endpoint or in relation to all-cause mortality and the rest, as regards the type of clopidogrel used, i.e. original or generic (all *p* \> 0.10) ([Table I](#t0001){ref-type="table"}).

In [Table II](#t0002){ref-type="table"} two multi-adjusted models that were developed in order to evaluate the association between the clinical endpoint at 12-months of follow-up and the clopidogrel treatment are presented. As can be seen, the type of clopidogrel used (original versus generic form) as well as the transition from original to generic clopidogrel use, did not significantly affect the 12-month clinical outcome. Moreover, the interactions between the form of clopidogrel used and sociodemographic (i.e. gender, region of residence), clinical (i.e. BMI, discharge status and history of hypercholesterolaemia, hypertension, diabetes mellitus), and lifestyle (smoking status) characteristics on the clinical outcome, were evaluated. Stratified analyses were also performed by the aforementioned factors. As can be seen in [Figures 1](#f0001){ref-type="fig"} and [2](#f0002){ref-type="fig"}, the type of clopidogrel (i.e. generic vs. original) as well as the potential transition from the original to generic formulation did not significantly affect the 12-month clinical endpoint in all stratified analyses. This sensitivity analysis suggests that the use of either original or generic form of clopidogrel has similar effects on the 12-month clinical outcome in ACS patients, irrespective to their age, gender, region of residence, or their CVD risk factor profile.

###### 

Results from logistic regression analysis presenting the association of antiplatelet agents therapy (generic vs. original clopidogrel) (Model 1) and the pattern of clopidogrel treatment (transition from original to generic clopidogrel vs. exclusive use of generic clopidogrel) (Model 2), with the incidence of the clinical endpoint (the composite of recurrent AMI or ischaemic stroke, cardiac deaths, or hospitalisation due to a major haemorrhage) in the 12-month follow-up period (*n* = 1194)

  Model 1                                                          OR       95% CI
  ---------------------------------------------------------------- -------- ------------
  Antiplatelet treatment (generic vs. original clopidogrel)        1.11     0.45--1.71
  Discharge status (acute myocardial infarction/unstable angina)   3.07     2.30--4.03
  Age (per 1 year)                                                 1.04     1.01--1.07
  Female gender                                                    0.80     0.40--1.60
  Current smoking (y/n)                                            1.19     0.62--2.30
  Region of residence (Aegean vs. urban)                           1.30     0.70--2.39
  Body mass index (per 1 kg/m^2^)                                  1.01     0.97--1.05
  Hypertension (y/n)                                               0.94     0.46--1.89
  Hypercholesterolaemia (y/n)                                      0.79     0.40--1.54
  Diabetes mellitus (y/n)                                          1.58     0.85--2.92
  Family CVD history (y/n)                                         0.86     0.36--2.05
  **Model 2**                                                      **OR**   **95% CI**
  Transition from original to generic clopidogrel, y/n             1.13     0.62--2.06
  Discharge status (acute myocardial infarction/unstable angina)   3.02     1.55--3.90
  Age (per 1 year)                                                 1.04     1.01--1.07
  Female gender                                                    0.82     0.41--1.65
  Current smoking (y/n)                                            1.09     0.56--2.12
  Region of residence (Aegean vs. urban)                           1.15     0.61--2.14
  Body mass index (per 1 kg/m^2^)                                  1.01     0.96--1.05
  Hypertension (y/n)                                               0.93     0.46--1.90
  Hypercholesterolaemia (y/n)                                      0.76     0.39--1.49
  Diabetes mellitus (y/n)                                          1.45     0.78--2.70
  Family CVD history, (y/n)                                        0.67     0.28--1.63

OR -- odds ratio, 95% CI -- 95% confidence interval, CVD -- cardiovascular disease.

![Stratified analysis evaluating the association between the clopidogrel formulation (generic vs. original) and 12-month clinical composite endpoint. Odds ratios (dots) and their 95% confidence intervals (horizontal lines) were obtained through multivariate logistic regression analysis adjusted for age, sex, body mass index, region of residence, discharge status, history of hypertension, hypercholesterolemia, diabetes mellitus and family CVD history. Vertical and horizontal axes are intersected in the value 1; values in the right side indicate a favorable effect of original clopidogrel while values in the left side indicate a favorable effect of generic clopidogrel\
OR -- odds ratio, 95% CI -- 95% confidence interval, CVD -- cardiovascular disease.](AMS-16-5-40812-g001){#f0001}

![Stratified analysis evaluating the association between the exclusive use of generic versus transition from original to generic clopidogrel and 12-month clinical composite endpoint. Odds ratios (dots) and their 95% confidence intervals (horizontal lines) were obtained through multivariate logistic regression analysis adjusted for age, sex, body mass index, region of residence, discharge status, history of hypertension, hypercholesterolemia, diabetes mellitus and family CVD history. Vertical and horizontal axes are intersected in the value 1; values in the right side indicate a harmful effect while values in the left side indicate a protective effect of the tested variable\
OR -- odds ratio, 95% CI -- 95% confidence interval, CVD -- cardiovascular disease](AMS-16-5-40812-g002){#f0002}

Discussion {#sec4}
==========

The 12 months following an ACS event are of crucial importance for these patients. In this work it was revealed that at 12 months of follow-up, the clinical endpoint had occurred in a relatively low number of patients, below 5% of the total number of ACS patients who participated in the study, without any differences between genders, or between those patients living in mainland urban areas or on the islands. As for the all-cause mortality rate, this was low, probably due to the short-term follow-up period, the result of which was in accordance with our previously published study using the same generic clopidogrel formulation \[[@cit0016]\]. Furthermore, the use of the generic clopidogrel besylate was quite high (81--90%) in both urban and insular areas. Despite the limitations due to the observational nature of the study, this work highlights the increasing use of this low-cost generic clopidogrel in the management of CVD patients. However, it should be stated that the use of generic clopidogrel, even in overall high levels, was lower in insular areas compared with the urban centres. The expected lower educational level of the islanders compared to the residents in urban centres may mediate this difference \[[@cit0004]\].

A number of studies aiming to compare the efficacy and safety of generic versus original clopidogrel in CVD, including ACS patients, have shown conflicting results, with some studies reporting no differences and others suggesting important potential differences \[[@cit0016]--[@cit0020]\]. A very recent study assessed primary causative adverse events after brand clopidogrel and generic clopidogrel use in the Food and Drug Administration (FDA) Adverse Event Reporting System. The authors demonstrated that death reports were higher, whereas the rates of cardiac, haemorrhagic, and skin complications were less common for original clopidogrel compared with generic clopidogrel formulations \[[@cit0021]\]. Therefore, it is important that any efficacy or safety concern arising from the use of generic clopidogrel in CVD patients should be referred to the specific product used. In this regard, our previous studies have demonstrated that the pharmacodynamic potency as well as clinical efficacy and safety profile of the generic clopidogrel used in the present study are similar to those of the original drug \[[@cit0016], [@cit0022]--[@cit0024]\]. In the present work, the 12-month composite clinical endpoint remained quite low, with the use of generic clopidogrel being at a high level, while multivariate analysis revealed that original and generic forms of clopidogrel did not present any significant differences in terms of the examined efficacy outcome ([Table II](#t0002){ref-type="table"}). At the same time, the bleeding events remained low, probably suggesting safety equivalence as well. The present study also demonstrated that the generic clopidogrel formulation is equally effective in different subgroups, including different genders, within the studied population. Stratified analyses with gender as strata are important to confirm the drug efficacy against major events as well as its safety \[[@cit0025]\]. In the present work, both the statistical (in terms of *p* for interaction) and the clinical (in terms of stratified risk analysis) gender--treatment interaction were evaluated, but no significant differences were observed ([Figures 1](#f0001){ref-type="fig"} and [2](#f0002){ref-type="fig"}). Antiplatelet treatment with clopidogrel has been investigated separately in men and women; non-significant outcomes were revealed in a meta-analysis of five clinical trials with more than 79,000 participants, 30% of whom were women \[[@cit0026]\]. However, in these meta-analysed data men presented almost twice as high recurrent CVD risk reduction compared to women (i.e. 16% vs. 7%), while women exhibited higher bleeding risk (43% vs. 22%) \[[@cit0026]\]. In the previous literature, 60% of all patients admitted to the hospital for adverse drug effects are women, which can be predominantly attributed to dose-related reasons \[[@cit0027]\].

Living in remote areas of a country has long been investigated in relation to the prevalence and incidence of cardiometabolic risk factors and CVDs, mainly due to poorer health care services resulting in limited accessibility and/or delayed arrival at hospital \[[@cit0008], [@cit0028]\]. In addition, it is expected that in these areas the target attainment in important risk factors, such as low-density lipoprotein cholesterol (LDL-C) and hypertension, the combination of which significantly increase the CVD risk, may be suboptimal as it being reported to occur even in the urban areas \[[@cit0029], [@cit0030]\]. Despite that, the present study demonstrated that patients in Aegean islands presented slightly lower, not statistically significant, hypercholesterolaemia, hypertension, and diabetes mellitus prevalence, and they were less likely to smoke ([Table I](#t0001){ref-type="table"}). This cardiometabolic profile with lower risk factor burden could be attributed to the healthier lifestyle habits \[[@cit0031]\]. Nonetheless, the overall discrepancies in terms of clinical factors were not so evident, depicting that the current dietary habits of Mediterranean islands are not a reflection of the past; shifts towards unhealthier habits have been recorded \[[@cit0010]\]. In the present work the clinical endpoint at 12 months of follow-up was evaluated in ACS patients with clinical and demographic characteristics as strata, in relation to the type of clopidogrel used, without revealing significant differences.

All patients were treated with clopidogrel instead of ticagrelor or prasugrel as the ESC guidelines recommend for ACS patients \[[@cit0032]\]. This is primarily due to the severe economic problems during the enrolment period, which had as a consequence the prescription of a lower cost antiplatelet, compared with ticagrelor or prasugrel, i.e. clopidogrel. This led to better compliance of the patients participating in the present study. The findings of the present work should be considered with caution and without any causal interpretations, due to the observational nature of the study from which these results were extracted.

The aforementioned limitations are compensated by several strengths, which should be stated. Firstly, this is one of the very few studies to examine the role of generic vs. original antiplatelet treatment in CVD recurrence under the context of a "real-world" (i.e. epidemiological) study, in contrast with the strictly controlled environment of clinical trials. Secondly, a strength of the present work is related with the provision of sensitivity analysis evaluating the principal research hypothesis according to participants' gender, age, area of residence, and other factors. Lastly, to the best of our knowledge the transition from original to generic antiplatelet treatment and its association with CVD recurrence is an inadequately discussed issue in the previous literature.

In conclusion, the use of generic clopidogrel besylate was quite high in both urban and insular areas of Greece and had similar efficacy and safety profile as the original clopidogrel salt, supporting the routine use of this low-cost generic clopidogrel in the management of CVD patients.
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